How to Address the Superbug Crisis?

Superbug Crisis

Superbugs are drug-resistant infections and have been described as one of the greatest threats to global health and development. The global superbug crisis is a complex, long-term problem. The overuse of antibiotics has led to the spread of drug resistance and the spread of drug-resistant genes among bacteria, which could affect millions of people worldwide. And there are many other surprising aspects to this crisis.

It takes the spread of bacteria in animal and human populations to create superbugs.
Little funding is currently devoted to antibiotic resistance and resistance gene research.
Treatment of drug-resistant infections is very expensive and lengthy.
The right incentives for making new antibiotics are not in place.

Address the Superbug Crisis

Give diagnostic answers to the superbug crisis. Help better target therapies with the development of a rapid bacterial identification and drug resistance marker platform.
We now need new and better antibiotics to reverse the course of this crisis.
Research and develop specific therapies for common and severe superbug infections.

Diagnostic Solutions

Solutions to combat antibiotic-resistant superbugs that do not involve the development of new drugs are emerging. This important tool is rapid diagnostics. Diagnostics are a way to identify superbugs and characterize drug resistance. The current development of simple and rapid resistance diagnostics is instrumental in curbing antibiotic resistance.

Rapid bacterial identification
Antibiotic resistance identification

Learn More

Identification by phage

Enzyme Identification

Identification by DNA nanosensor

Antibiotic susceptibility assay

Resistance genes detection

Treatment Solutions

Another important measure to address the superbug crisis is a therapeutic solution. First, we must use antibiotics judiciously and in moderation, which will help slow the rise of antibiotic resistance, but will not stop it. Second, we need to vigorously develop newer, more effective antibacterial drugs.

The most common antibiotics used to treat bacterial infections are beta-lactam antibiotics, such as cephalosporins and carbapenems. A number of current research findings provide insights into new treatments for bacterial infections.

Common Therapies Specific Therapies

Antimicrobial Peptides

AMPs have desirable properties such as rapid action, low potential for resistance and the ability to kill multi-drug resistant bacteria. We need to find antimicrobial peptides with high therapeutic potential, study and exploit their properties, and design and optimize peptides with optimal therapeutic potential.

Antibiotic Adjuvants

Antibiotic adjuvants make antibiotics great again. Combination therapy with an existing antibiotic and an enhancing adjuvant, which would re-endow the antibiotic agent to be effective against the resistant strain of interest. We need to discuss the innovative possibilities of antimicrobial adjuvants.

Monoclonal Antibodies

Monoclonal antibodies (mAb) have achieved remarkable clinical success in several areas. mAb can treat bacterial infections through a variety of mechanisms. More antibacterial mAb have been developed in recent years, and some candidates are in preclinical or clinical development.

Bacteriophage Therapies

Bacteriophages are the natural enemies of bacteria. Phage therapy has been used for a century to treat bacterial infections, but is still in the experimental treatment phase. More research is needed to enable the rapid identification and use of phages and bacteria in clinical applications.

Vaccine

The vaccine helps reduce the risk of antibiotic resistance. Most importantly, while superbugs are resistant to drugs, they do not become resistant to vaccines. Although vaccines are effective in fighting antibiotic resistance, we currently do not take full advantage of them.

Specific Therapies

We are currently faced with the challenge of multiple superbug infections. In addition to the development of generic therapies for different species of bacteria, we should develop specific therapies for each superbug to improve the efficiency of treatment.

All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.